Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 70/100

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Key Takeaway: Insmed Incorporated, a biopharmaceutical company, announced the granting of inducement awards to 34 new employees, in accordance with NASDAQ Listing Rule 5635(c)(4). The approved inducements consist of options to purchase a total of 453,940 shares of the company’s stock at an exercise price of $19.24 per share. These options feature a 10-year term and a four-year vesting schedule, highlighting Insmed's strategy to attract and retain talent as it expands operations in treating serious and rare diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed granted inducement awards to 34 new employees, indicating company growth.
  • The options provided are part of a long-term incentive to attract talent.
  • Insmed is actively expanding its workforce to support its mission.

Full Press Release Details

BRIDGEWATER, N.J. , June 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 34 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
In connection with the commencement of their employment, the employees received options on June 1, 2023 to purchase an aggregate 453,940 shares of Insmed common stock at an exercise price of $19.24 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey , with a footprint across Europe and in Japan . For more information, visit www.insmed.com .
Bryan Dunn Executive Director, Investor Relations Insmed (646) 812-4030 [email protected]
Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 [email protected]
Mandy Fahey Executive Director, Corporate Communications Insmed (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

What are inducement awards at Insmed?

Inducement awards are granted to new employees as an incentive for joining Insmed.

How many employees received options at Insmed?

A total of 34 new employees received options to purchase shares.

What is the exercise price for the granted options?

The exercise price for the options is set at $19.24 per share.

What is the vesting schedule for the options?

Options vest over four years, starting with 25% on the first anniversary.

What is Insmed's primary focus as a company?

Insmed focuses on developing therapies for serious and rare diseases.

Last updated: Jun 6, 2023